Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 15 March 2013 | By Alexander Gaffney, RAC,
A safety warning released on 14 March 2013 by the US Food and Drug Administration (FDA) states that regulators have become aware of and are investigating reports that incretin mimetic drugs for type-2 diabetes could possibly increase a patient's risk of developing pancreatitis and cancer.
The drugs-which include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto)-mimic the body's natural hormones to regulate the release of insulin and control type-2 diabetes.
Based on what FDA called an "examination of a small number of pancreatic tissue specimens taken from patients after they died," it said it is concerned about "potential pancreatic toxicity" associated with the drugs.
FDA has been aware for years of a loose association between two of the drugs , exenatide and sitagliptin, and acute pancreatitis. The new reports both expand the number of drugs potentially associated with the risks and notes the potential risk of developing cancer as well.
These associations are not yet conclusive, FDA added. Accordingly, the agency said it intends to study the issue in further depth and participate in a June 2013 meeting being run by the National Cancer Institute (NCI) on the association between pancreatitis, diabetes and pancreatic cancer.
Pancreatitis is a severe condition marked by inflammation of the pancreas that requires immediate medical treatment.
Regulatory Focus newsletters
All the biggest regulatory news and happenings.